Stock Analysts’ Updated EPS Estimates for December 20th (ALMS, AQST, ARWR, BKD, BLND, CAG, CMPR, CRSP, CSL, CTAS)

Stock Analysts’ updated eps estimates for Friday, December 20th:

Alumis (NASDAQ:ALMS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $26.00 target price on the stock.

Aquestive Therapeutics (NASDAQ:AQST) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $10.00 target price on the stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $80.00 price target on the stock.

Brookdale Senior Living (NYSE:BKD) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $8.00 price target on the stock.

Brookdale Senior Living (NYSE:BKD) had its outperform rating reaffirmed by analysts at Macquarie. The firm currently has a $8.00 price target on the stock.

Blend Labs (NYSE:BLND) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $5.75 price target on the stock.

Conagra Brands (NYSE:CAG) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $29.00 target price on the stock.

Cimpress (NASDAQ:CMPR) had its outperform rating reissued by analysts at Barrington Research. Barrington Research currently has a $119.00 price target on the stock.

CRISPR Therapeutics (NASDAQ:CRSP) had its market outperform rating reissued by analysts at JMP Securities. They currently have a $86.00 target price on the stock.

Carlisle Companies (NYSE:CSL) had its outperform rating reissued by analysts at Oppenheimer Holdings Inc.. The firm currently has a $495.00 target price on the stock, down from their previous target price of $505.00.

Cintas (NASDAQ:CTAS) had its sector perform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $215.00 price target on the stock.

Cytokinetics (NASDAQ:CYTK) had its buy rating reissued by analysts at HC Wainwright. They currently have a $120.00 target price on the stock.

Dollar Tree (NASDAQ:DLTR) had its market perform rating reiterated by analysts at Telsey Advisory Group. They currently have a $75.00 target price on the stock.

Darden Restaurants (NYSE:DRI) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $200.00 price target on the stock, up from their previous price target of $182.00.

FuelCell Energy (NASDAQ:FCEL) had its hold rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a $12.00 target price on the stock.

FactSet Research Systems (NYSE:FDS) had its sector perform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $503.00 target price on the stock.

Fennec Pharmaceuticals (NASDAQ:FENC) had its outperform rating reissued by analysts at Wedbush. They currently have a $13.00 target price on the stock.

Goodyear Tire & Rubber (NASDAQ:GT) had its hold rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $10.00 price target on the stock.

Humacyte (NASDAQ:HUMA) had its buy rating reiterated by analysts at D. Boral Capital. D. Boral Capital currently has a $25.00 target price on the stock.

Humacyte (NASDAQ:HUMA) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $15.00 target price on the stock, up from their previous target price of $12.00.

ImmunityBio (NASDAQ:IBRX) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $30.00 target price on the stock.

InflaRx (NASDAQ:IFRX) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $8.00 target price on the stock.

Ionis Pharmaceuticals (NASDAQ:IONS) had its outperform rating reiterated by analysts at William Blair.

Ionis Pharmaceuticals (NASDAQ:IONS) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $60.00 price target on the stock.

Largo (NYSE:LGO) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $4.20 price target on the stock.

Lumen Technologies (NYSE:LUMN) had its sector perform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $4.25 target price on the stock, up from their previous target price of $4.00.

LXP Industrial Trust (NYSE:LXP) had its market perform rating reaffirmed by analysts at JMP Securities.

Middleby (NASDAQ:MIDD) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a $155.00 target price on the stock.

Neurocrine Biosciences (NASDAQ:NBIX) had its hold rating reaffirmed by analysts at Needham & Company LLC.

NIKE (NYSE:NKE) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $84.00 price target on the stock.

Oruka Therapeutics (NASDAQ:ORKA) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $45.00 price target on the stock.

Paychex (NASDAQ:PAYX) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $148.00 price target on the stock.

Prothena (NASDAQ:PRTA) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $48.00 price target on the stock, down from their previous price target of $84.00.

Personalis (NASDAQ:PSNL) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $7.25 target price on the stock.

Pyxis Oncology (NASDAQ:PYXS) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $8.00 price target on the stock, down from their previous price target of $10.00.

Pyxis Oncology (NASDAQ:PYXS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $5.00 target price on the stock, down from their previous target price of $7.00.

Rezolve AI (NASDAQ:RZLV) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $8.00 target price on the stock.

Constellation Brands (NYSE:STZ) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $280.00 price target on the stock.

Suncor Energy (NYSE:SU) (TSE:SU) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $66.00 target price on the stock.

Veru (NASDAQ:VERU) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $3.00 price target on the stock.

Verrica Pharmaceuticals (NASDAQ:VRCA) had its hold rating reiterated by analysts at Needham & Company LLC.

Vertex Pharmaceuticals (NASDAQ:VRTX) had its hold rating reissued by analysts at Needham & Company LLC.

Petco Health and Wellness (NASDAQ:WOOF) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $6.00 target price on the stock.

Xometry (NASDAQ:XMTR) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $48.00 price target on the stock.